Ethos Discovery Stratified Outcomes for Lymphoma in Dogs (SOLID) Study: Informing Subclassification & Prognosis

Classification of LSA in dogs is based on anatomic location, histologic criteria, and immunophenotypic characteristics. Histologic classification currently follows the Revised European American Lymphoma/World Health Organization system incorporating anatomic, morphologic, and immunophenotypic criteria to enable accurate diagnosis and classification of LSA subtypes in dogs. However, LSA is not a single disease and classification by subtype becomes increasingly important as clinical studies are performed to correlate the various categories of disease with biological behavior, response to treatment, and prognosis. In people, genetic characterization of non-Hodgkin’s lymphoma is routinely used in diagnosis and subcategorization of LSA into prognostic categories. Investigations into the molecular landscape of canine LSA samples via cytogenetic and gene expression analysis have shown potential for both diagnostic and prognostic utility, but clinical correlates are currently preliminary and high evidence data defining genomic subclassifications of LSA and the identification of biomarkers associated with biologic behavior and response to treatment are currently lacking. We now seek to address these scientific and translational gaps through the launch of the Ethos Stratification of Outcomes for Lymphoma in Dogs (Ethos-SOLID) clinical trial which will identify molecular correlates for intermediate- to high-grade B and T cell canine multicentric LSA. Using complementary genomic, transcriptomic, and liquid biopsy platforms, we will identify and refine molecular subtypes of LSA characterized by molecular alterations. The goals of our study are to: (1) develop foundational knowledge and stratification of the distinct, molecular subtypes of canine LSA and (2) identify molecularly informed biomarkers associated with clinical response, disease burden, and cancer progression.